- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Daniel F. Donovan (Dan)
Insights 21 results
Client Alert
December 30, 2021
Select Subcommittee on the Coronavirus Crisis Ends 2021 With Several Open Investigations and Promises for Continued Oversight Across Industries
Client Alert
Client Alert
July 2, 2021
Congressional Investigations in the 117th Congress: U.S. Senate Oversight Activities Ramp Up
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Client Alert
February 26, 2021
Financial Services Industry Back Under Congress’ Microscope
Energy Law Exchange
February 5, 2021
Georgia Results Flip the Senate and Will Lead to More Congressional Investigations
Client Alert
January 29, 2021
New Drivers, Same Bumpy Ride
Newsletter
January 21, 2021
Energy Newsletter - January 2021
Client Alert
January 8, 2021
Georgia Results Flip the Senate and Will Lead to More Congressional Investigations
Client Alert
December 30, 2020
House Democrats Will Extend Historic Oversight Subcommittee on the Coronavirus Crisis into the 117th Congress
Thought Leadership
December 17, 2020
2020 Post-Election Commentary
Client Alert
July 30, 2020
Trump Administration Continues to Promote Drug Importation as a Way to Lower the Cost of Prescription Drugs